FDA clears first gene-altering therapy — ‘a living drug’ — for childhood leukemia – Washington Post
NPR |
FDA clears first gene-altering therapy — 'a living drug' — for childhood leukemia
Washington Post Unlike some experimental gene approaches, the Novartis treatment, called CAR T-cell therapy, doesn't replace disease-causing genes with healthy ones. Instead, in a complicated and personalized process, white blood cells called T cells are extracted … FDA Approves First Gene Therapy For Leukemia Novartis Sets a Price of $475000 for CAR T-Cell Therapy FDA approval brings first gene therapy to the United States |
